|
1
|
Ostrom QT, Gittleman H, Xu J, Kromer C,
Wolinsky Y, Kruchko C and Barnholtz-Sloan JS: CBTRUS statistical
report: Primary brain and other central nervous system tumors
diagnosed in the United states in 2009–2013. Neuro Oncol. 18 (Suppl
5):v1–v75. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Louis DN, Perry A, Reifenberger G, von
Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD,
Kleihues P and Ellison DW: The 2016 world health organization
classification of tumors of the central nervous system: A summary.
Acta Neuropathol. 131:803–820. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Jan CI, Tsai WC, Harn HJ, Shyu WC, Liu MC,
Lu HM, Chiu SC and Cho DY: Predictors of response to autologous
dendritic cell therapy in glioblastoma multiforme. Front Immunol.
9:7272018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
López GY, Van Ziffle J, Onodera C, Grenert
JP, Yeh I, Bastian BC, Clarke J, Oberheim Bush NA, Taylor J, Chang
S, et al: The genetic landscape of gliomas arising after
therapeutic radiation. Acta Neuropathol. 137:139–150. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Gong J, Zhou Y, Liu D and Huo J: F-box
proteins involved in cancer-associated drug resistance. Oncol Lett.
15:8891–8900. 2018.PubMed/NCBI
|
|
6
|
Wang Z, Liu P, Inuzuka H and Wei W: Roles
of F-box proteins in cancer. Nat Rev Cancer. 14:233–247. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhang Y, Zvi YS, Batko B, Zaphiros N,
O'Donnell EF, Wang J, Sato K, Yang R, Geller DS, Koirala P, et al:
Down-regulation of Skp2 expression inhibits invasion and lung
metastasis in osteosarcoma. Sci Rep. 8:142942018. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lee SH and McCormick F: Downregulation of
Skp2 and p27/Kip1 synergistically induces apoptosis in T98G
glioblastoma cells. J Mol Med (Berl). 83:296–307. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ding L, Li R, Sun R, Zhou Y, Zhou Y, Han
X, Cui Y, Wang W, Lv Q and Bai J: S-phase kinase-associated protein
2 promotes cell growth and motility in osteosarcoma cells. Cell
Cycle. 16:1547–1555. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sonoda H, Inoue H, Ogawa K, Utsunomiya T,
Masuda TA and Mori M: Significance of skp2 expression in primary
breast cancer. Clin Cancer Res. 12:1215–1220. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Geng Q, Liu J, Gong Z, Chen S, Chen S, Li
X, Lu Y, Zhu X, Lin HK and Xu D: Phosphorylation by mTORC1
stablizes Skp2 and regulates its oncogenic function in gastric
cancer. Mol Cancer. 16:832017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Huang T, Yang L, Wang G, Ding G, Peng B,
Wen Y and Wang Z: Inhibition of Skp2 sensitizes lung cancer cells
to paclitaxel. Onco Targets Ther. 10:439–446. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Totary-Jain H, Sanoudou D, Dautriche CN,
Schneller H, Zambrana L and Marks AR: Rapamycin resistance is
linked to defective regulation of Skp2. Cancer Res. 72:1836–1843.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Li W, Li F, Zhu Y and Song D: Physcion
8-O-β- glucopyranosideregulates cell cycle, apoptosis, and invasion
in glioblastoma cells through modulating Skp2. Biomed Pharmacother.
95:1129–1138. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ouyang J, Xu H, Li M, Dai X, Fu F, Zhang X
and Lan Q: Paeoniflorin exerts antitumor effects by inactivating S
phase kinase-associated protein 2 in glioma cells. Oncol Rep.
39:1052–1062. 2018.PubMed/NCBI
|
|
16
|
Schiffer D, Cavalla P, Fiano V, Ghimenti C
and Piva R: Inverse relationship between p27/Kip.1 and the F-box
protein Skp2 in human astrocytic gliomas by immunohistochemistry
and Western blot. Neurosci Lett. 328:125–128. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Saigusa K, Hashimoto N, Tsuda H, Yokoi S,
Maruno M, Yoshimine T, Aoyagi M, Ohno K, Imoto I and Inazawa J:
Overexpressed Skp2 within 5p amplification detected by array-based
comparative genomic hybridization is associated with poor prognosis
of glioblastomas. Cancer Sci. 96:676–683. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Reifenberger G, Wirsching HG,
Knobbe-Thomsen CB and Weller M: Advances in the molecular genetics
of gliomas-implications for classification and therapy. Nat Rev
Clin Oncol. 14:434–452. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Cohen AL, Holmen SL and Colman H: IDH1 and
IDH2 mutations in gliomas. Curr Neurol Neurosci Rep. 13:3452013.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Nonoguchi N, Ohta T, Oh JE, Kim YH,
Kleihues P and Ohgaki H: TERT promoter mutations in primary and
secondary glioblastomas. Acta Neuropathol. 126:931–937. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Stone JG, Siedlak SL, Tabaton M, Hirano A,
Castellani RJ, Santocanale C, Perry G, Smith MA, Zhu X and Lee HG:
The cell cycle regulator phosphorylated retinoblastoma protein is
associated with tau pathology in several tauopathies. J Neuropathol
Exp Neurol. 70:578–587. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Thwaites MJ, Cecchini MJ and Dick FA:
Analyzing RB and E2F during the G1-S transition. Methods Mol Biol.
1170:449–461. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Saadeh FS, Mahfouz R and Assi HI: EGFR as
a clinical marker in glioblastomas and other gliomas. Int J Biol
Markers. 33:22–32. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Dick FA and Rubin SM: Molecular mechanisms
underlying RB protein function. Nat Rev Mol Cell Biol. 14:297–306.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Shintani S, Li C, Mihara M, Yano J,
Terakado N, Nakashiro K and Hamakawa H: Gefitinib (‘Iressa’,
ZD1839), an epidermal growth factor receptor tyrosine kinase
inhibitor, up-regulates p27KIP1 and induces G1 arrest in oral
squamous cell carcinoma cell lines. Oral Oncol. 40:43–51. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Feng YB, Lin DC, Shi ZZ, Wang XC, Shen XM,
Zhang Y, Du XL, Luo ML, Xu X, Han YL, et al: Overexpression of PLK1
is associated with poor survival by inhibiting apoptosis via
enhancement of survivin level in esophageal squamous cell
carcinoma. Int J Cancer. 124:578–588. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Faulkner C, Palmer A, Williams H, Wragg C,
Haynes HR, White P, DeSouza RM, Williams M, Hopkins K and Kurian
KM: EGFR and EGFRvIII analysis in glioblastoma as therapeutic
biomarkers. Br J Neurosurg. 29:23–29. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Cai HQ, Wang PF, Zhang HP, Cheng ZJ, Li
SW, He J, Zhang Y, Hao JJ, Wang MR, Yan CX and Wan JH:
Phosphorylated Hsp27 is mutually exclusive with ATRX loss and the
IDH1(R132H) mutation and may predict better prognosis among
glioblastomas without the IDH1 mutation and ATRX loss. J Clin
Pathol. 71:702–707. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Soni D, King JA, Kaye AH and Hovens CM:
Genetics of glioblastoma multiforme: Mitogenic signaling and cell
cycle pathways converge. J Clin Neurosci. 12:1–5. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Nakayama KI, Hatakeyama S and Nakayama K:
Regulation of the cell cycle at the G1-S transition by proteolysis
of cyclin E and p27Kip1. Biochem Biophys Res Commun. 282:853–860.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Signoretti S, Di Marcotullio L, Richardson
A, Ramaswamy S, Isaac B, Rue M, Monti F, Loda M and Pagano M:
Oncogenic role of the ubiquitin ligase subunit Skp2 in human breast
cancer. J Clin Invest. 110:633–641. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Lu M, Ma J, Xue W, Cheng C, Wang Y, Zhao
Y, Ke Q, Liu H, Liu Y, Li P, et al: The expression and prognosis of
FOXO3a and Skp2 in human hepatocellular carcinoma. Pathol Oncol
Res. 15:679–687. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Elsherif E, Elbaky TA, Elserafy F, Elkady
N, Dawood M, Gaber MA, Badawy A and Gharabawy ME: β-catenin and
SKP2 proteins as predictors of grade and stage of non-muscle
invasive urothelial bladder carcinoma. Chin Clin Oncol.
5:62016.PubMed/NCBI
|
|
35
|
Raucher D, Dragojevic S and Ryu J:
Macromolecular drug carriers for targeted glioblastoma therapy:
Preclinical studies, challenges, and future perspectives. Front
Oncol. 8:6242018. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Wang L, Ye X, Cai X, Su J, Ma R, Yin X,
Zhou X, Li H and Wang Z: Curcumin suppresses cell growth and
invasion and induces apoptosis by down-regulation of Skp2 pathway
in glioma cells. Oncotarget. 6:18027–18037. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Chen VC, Hsieh YH, Chen LJ, Hsu TC and
Tzang BS: Escitalopram oxalate induces apoptosis in U-87MG cells
and autophagy in GBM8401 cells. J Cell Mol Med. 22:1167–1178.
2018.PubMed/NCBI
|
|
38
|
Huang MH, Lin SZ, Lin PC, Chiou TW, Harn
YW, Ho LI, Chan TM, Chou CW, Chuang CH, Su HL and Harn HJ: Brain
tumor senescence might be mediated by downregulation of S-phase
kinase-associated protein 2 via butylidenephthalide leading to
decreased cell viability. Tumour Biol. 35:4875–4884. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Davidovich S, Ben-Izhak O, Shapira M,
Futerman B and Hershko DD: Over-Expression of Skp2 is associated
with resistance to preoperative doxorubicin-based chemotherapy in
primary breast cancer. Breast Cancer Res. 10:R632008. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Xu T, Chen J, Zhu D, Chen L, Wang J, Sun
X, Hu B and Duan Y: Egg antigen p40 of schistosoma japonicum
promotes senescence in activated hepatic stellate cells via
SKP2/P27 signaling pathway. Sci Rep. 7:2752017. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Tan Y, Zhou G, Wang X, Chen W and Gao H:
USP18 promotes breast cancer growth by upregulating EGFR and
activating the AKT/Skp2 pathway. Int J Oncol. 53:371–383.
2018.PubMed/NCBI
|
|
42
|
Eckel-Passow JE, Lachance DH, Molinaro AM,
Walsh KM, Decker PA, Sicotte H, Pekmezci M, Rice T, Kosel ML,
Smirnov IV, et al: Glioma groups based on 1p/19q, IDH, and TERT
promoter mutations in tumors. N Engl J Med. 372:2499–2508. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Diplas BH, He X, Brosnan-Cashman JA, Liu
H, Chen LH, Wang Z, Moure CJ, Killela PJ, Loriaux DB, Lipp ES, et
al: The genomic landscape of TERT promoter wildtype-IDH wildtype
glioblastoma. Nat Commun. 9:20872018. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Wang JB, Dong DF, Wang MD and Gao K: IDH1
overexpression induced chemotherapy resistance and IDH1 mutation
enhanced chemotherapy sensitivity in Glioma cells in vitro and in
vivo. Asian Pac J Cancer Prev. 15:427–432. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Miyata S, Urabe M, Gomi A, Nagai M,
Yamaguchi T, Tsukahara T, Mizukami H, Kume A, Ozawa K and Watanabe
E: An R132H mutation in isocitrate dehydrogenase 1 enhances p21
expression and inhibits phosphorylation of retinoblastoma protein
in glioma cells. Neurol Med Chir (Tokyo). 53:645–654. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Chien MN, Yang PS, Hsu YC, Liu TP, Lee JJ
and Cheng SP: Transcriptome analysis of papillary thyroid cancer
harboring telomerase reverse transcriptase promoter mutation. Head
Neck. 40:2528–2537. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Jafri MA, Ansari SA, Alqahtani MH and Shay
JW: Roles of telomeres and telomerase in cancer, and advances in
telomerase-targeted therapies. Genome Med. 8:692016. View Article : Google Scholar : PubMed/NCBI
|
